Loading institutional data...
Loading institutional data...
Held by 295 of 5,944 reporting institutions (94th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2026
Each value shows its share of revenue below it (common-size).
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $870.4M 100.0% | $894.7M 100.0% | $924.2M 100.0% | $822.4M 100.0% | $527.2M 100.0% | $468.5M 100.0% | $418.2M 100.0% | $414.2M 100.0% | $397.9M 100.0% | $358.3M 100.0% |
| Cost of Revenue | $461.9M 53.1% | $473.3M 52.9% | $460.3M 49.8% | $416.5M 50.6% | $284.1M 53.9% | $253.4M 54.1% | $221.9M 53.1% | $222.3M 53.7% | $211.7M 53.2% | $189.6M 52.9% |
| Cost of Products | — | — | — | — | — | — | — | — | — | $156.6M 43.7% |
| Cost of Services | — | — | — | — | — | — | — | — | — | $33.1M 9.2% |
| Gross Profit | $408.5M 46.9% | $421.4M 47.1% | $463.9M 50.2% | $406.0M 49.4% | $243.0M 46.1% | $215.1M 45.9% | $196.3M 46.9% | $191.9M 46.3% | $186.3M 46.8% | $168.9M 47.1% |
| Research & Development | $18.4M 2.1% | $21.1M 2.4% | $22.5M 2.4% | $26.0M 3.2% | $17.0M 3.2% | $16.2M 3.5% | $14.8M 3.5% | $12.8M 3.1% | $10.9M 2.7% | $10.4M 2.9% |
| Selling, General & Admin | $245.1M 28.2% | $218.2M 24.4% | $199.9M 21.6% | $201.2M 24.5% | $82.7M 15.7% | $51.2M 10.9% | $44.3M 10.6% | $40.8M 9.8% | $38.3M 9.6% | $34.2M 9.5% |
| Total Operating Expenses | $430.1M 49.4% | $1.48B 165.7% | $405.3M 43.9% | $368.4M 44.8% | $184.4M 35.0% | $140.9M 30.1% | $128.8M 30.8% | $123.8M 29.9% | $116.1M 29.2% | $104.0M 29.0% |
| Operating Income | -$21.6M -2.5% | -$1.06B -118.6% | $58.6M 6.3% | $37.5M 4.6% | $58.6M 11.1% | $74.2M 15.8% | $67.5M 16.1% | $68.1M 16.4% | $70.2M 17.6% | $64.9M 18.1% |
| Interest Expense | $24.1M 2.8% | $38.1M 4.3% | $42.2M 4.6% | $27.3M 3.3% | — | — | — | — | — | — |
| Interest & Investment Income | — | $3.1M 0.3% | $6.4M 0.7% | $3.2M 0.4% | — | — | — | — | — | $838K 0.2% |
| Other Income (Expense), net | $12.6M 1.4% | -$72.1M -8.1% | -$72.9M -7.9% | -$59.6M -7.2% | $1.6M 0.3% | $1.1M 0.2% | $4.8M 1.1% | $4.9M 1.2% | $3.3M 0.8% | $1.7M 0.5% |
| Pretax Income | -$9.0M -1.0% | -$1.13B -126.6% | -$14.3M -1.5% | -$22.0M -2.7% | $60.2M 11.4% | $75.3M 16.1% | $72.3M 17.3% | $73.0M 17.6% | $73.5M 18.5% | $66.7M 18.6% |
| Income Tax Expense | -$1.1M -0.1% | -$41.1M -4.6% | -$4.9M -0.5% | $828K 0.1% | $11.9M 2.3% | $14.4M 3.1% | $12.8M 3.1% | $12.8M 3.1% | $10.3M 2.6% | $22.7M 6.3% |
| Net Income | -$7.9M -0.9% | -$1.09B -122.1% | -$9.4M -1.0% | -$22.9M -2.8% | $48.3M 9.2% | $60.9M 13.0% | $59.5M 14.2% | $60.2M 14.5% | $63.1M 15.9% | $43.8M 12.2% |
| Per Share | ||||||||||
| EPS (Basic) | $-0.04 | $-5.03 | $-0.04 | $-0.12 | $0.45 | $0.57 | $0.57 | $0.58 | $1.23 | $0.87 |
| EPS (Diluted) | $-0.04 | $-5.03 | $-0.04 | $-0.12 | $0.45 | $0.57 | $0.56 | $0.57 | $1.21 | $0.86 |
| Weighted Avg Shares (Basic) | 217.5M | 216.9M | 216.5M | 188.9M | 107.7M | 106.5M | 105.1M | 103.8M | 51.4M | 50.5M |
| Weighted Avg Shares (Diluted) | 217.5M | 216.9M | 216.5M | 188.9M | 108.0M | 107.1M | 105.7M | 104.8M | 52.1M | 51.2M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $12.83 today, the market must believe free cash flow compounds 30.8%/yr for a decade (off $32M normalized FCF).
The market's 30.8% is more optimistic than its 9-yr track record.
2-stage DCF · 0.22B shares · net debt $608M
mean -25.9% · volatility σ 66% · implied rate exceeded in 0/6 yrs
Central path = implied 30.8%/yr growth; shaded band = ±1σ (66%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $32M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -0%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $186M covers the $19M due within a year 9.6× over. Scheduled principal only (excludes interest & revolver draws). As of 2025-05-31 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~3.0% on $794M of debt.
Cash of $186M fully covers short-term debt of $0.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
No standout strengths flagged.
Is the profit real, and how strong is the balance sheet?
FY2026 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 36.1× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 53.7 | 53.1 | 54.1 | 53.9 | 50.6 | 49.8 | 52.9 | 53.1 |
| Gross Profit | 46.3 | 46.9 | 45.9 | 46.1 | 49.4 | 50.2 | 47.1 | 46.9 |
| R&D | 3.1 | 3.5 | 3.5 | 3.2 | 3.2 | 2.4 | 2.4 | 2.1 |
| SG&A | 9.8 | 10.6 | 10.9 | 15.7 | 24.5 | 21.6 | 24.4 | 28.2 |
| Operating Income | 16.4 | 16.1 | 15.8 | 11.1 | 4.6 | 6.3 | -118.6 | -2.5 |
| Income Tax | 3.1 | 3.1 | 3.1 | 2.3 | 0.1 | -0.5 | -4.6 | -0.1 |
| Net Income | 14.5 | 14.2 | 13.0 | 9.2 | -2.8 | -1.0 | -122.1 | -0.9 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on NEOG: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| NEOG | $2.8B | — | 35.9× | 3.2× | -2.7% | 46.9% | -0.9% | -0.4% | -0.3% | 8.4× | 295 |
Peers = companies sharing NEOG's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.